Keywords: Takeda, LigoCyte, Norovirus vaccine, Advinus Thera, Inflammation, CNS, Metabolic diseases
Takeda acquires vaccine maker LigoCyte; signs multi-drug discovery deal with Advinus
Article | 05 October 2012
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it is to acquire privately-held US vaccine producer LigoCyte Pharmaceuticals for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
